Note de episod
Drs Cooper and Choudhury discuss the evolving role of DLL3-targeting T-cell engagers in SCLC, with a focus on tarlatamab-dlle (Imdelltra) and how emerging trial data may reshape the current treatment paradigm across lines of therapy.
Site: audioboom.com

